Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 3/20 | 0.65 |
| ▸ | TNK2 | Q07912 | 15/20 | 0.51 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL170106 | 0.94 | BTK (0.57) | BTKTNK2RIPK1 | |
| SCHEMBL123306 | 0.91 | BTK (0.64) | BTKTNK2 | |
| SCHEMBL124142 | 0.90 | BTK (0.53) | BTKTNK2RIPK1 | |
| SCHEMBL124143 | 0.90 | BTK (0.53) | BTKTNK2RIPK1 | |
| SCHEMBL122059 | 0.90 | BTK (0.83) | BTKTNK2 | |
| SCHEMBL166399 | 0.89 | BTK (0.50) | BTKTNK2FFAR4 | |
| SCHEMBL16267066 | 0.89 | BTK (0.53) | BTKTNK2 | |
| SCHEMBL175282 | 0.88 | BTK (0.60) | BTKTNK2 | |
| SCHEMBL169925 | 0.88 | BTK (0.50) | BTKTNK2RIPK1 | |
| SCHEMBL122380 | 0.87 | BTK (0.53) | BTKTNK2RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111051449-B | Polysiloxane composition | 瓦克化学股份公司 | 2022-11-22 | — | — | CN | claimed |
| CN-111051449-A | Polysiloxane composition | 瓦克化学股份公司 | 2020-04-21 | — | — | CN | claimed |
| EP-2424368-B1 | PYRROLOTRIAZINE COMPOUNDS | LOCUS PHARMACEUTICALS INC (US) | 2014-12-31 | — | — | EP | claimed |
| US-8765754-B2 | Pyrrolotriazine compounds | LOCUS PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | claimed |
| US-20120232054-A1 | PYRROLOTRIAZINE COMPOUNDS | LOCUS PHARMACEUTICALS, INC. (US) | 2012-09-13 | — | — | US | claimed |
| EP-2424368-A1 | PYRROLOTRIAZINE COMPOUNDS | Locus Pharmaceuticals, Inc. (US) | 2012-03-07 | — | — | EP | claimed |
| WO-2010126960-A1 | PYRROLOTRIAZINE COMPOUNDS | LOCUS PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | WO | claimed |
| EP-0636471-B1 | Method for producing of a laminated glass | ASAHI GLASS CO LTD (JP) | 2001-03-21 | — | — | EP | claimed |
| US-5569537-A | CONTAINING MIXTURE OF COUPLING AGENTS ONLY ONE OF WHICH IS CAPABLE OF PROVIDING BOND STRENGTH BETWEEN GLASS AND RESIN; DURABILITY | ASAHI GLASS COMPANY LTD. (JP) | 1996-10-29 | — | — | US | claimed |
| EP-0636471-A1 | Laminated glass and method for its production | ASAHI GLASS COMPANY LTD. (JP) | 1995-02-01 | — | — | EP | claimed |
| CN-111051449-B | Polysiloxane composition | 瓦克化学股份公司 | 2022-11-22 | — | — | CN | disclosed |
| CN-111051449-A | Polysiloxane composition | 瓦克化学股份公司 | 2020-04-21 | — | — | CN | disclosed |
| US-20160074409-A1 | Treatment of Skeletal-Related Disorders | ROTHBAUM WAYNE (US) | 2016-03-17 | — | — | US | disclosed |
| US-8987344-B2 | Hardcoat composition | MITSUI CHEMICALS, INC. (JP) | 2015-03-24 | — | — | US | disclosed |
| EP-2424368-B1 | PYRROLOTRIAZINE COMPOUNDS | LOCUS PHARMACEUTICALS INC (US) | 2014-12-31 | — | — | EP | disclosed |
| EP-1728830-A2 | Fluorosilicone rubber composition and molded rubber article | Shin-Etsu Chemical Co., Ltd. (JP) | 2006-12-06 | — | — | EP | disclosed |
| EP-0636471-B1 | Method for producing of a laminated glass | ASAHI GLASS CO LTD (JP) | 2001-03-21 | — | — | EP | disclosed |
| US-5773178-A | Process for producing a patterned anisotropic polymeric film | JAPAN SYNTHETIC RUBBER CO, LTD. (JP) | 1998-06-30 | — | — | US | disclosed |
| US-5569537-A | CONTAINING MIXTURE OF COUPLING AGENTS ONLY ONE OF WHICH IS CAPABLE OF PROVIDING BOND STRENGTH BETWEEN GLASS AND RESIN; DURABILITY | ASAHI GLASS COMPANY LTD. (JP) | 1996-10-29 | — | — | US | disclosed |
| EP-0636471-A1 | Laminated glass and method for its production | ASAHI GLASS COMPANY LTD. (JP) | 1995-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160074409-A1 | Treatment of Skeletal-Related Disorders | SOST, COL2A1, CYP27B1 | BTK 4374/4885TNK2 1030/4885RIPK1 4329/4885 |
| US-20120232054-A1 | PYRROLOTRIAZINE COMPOUNDS | BTK, SYK, ZAP70 | BTK 1/4885TNK2 511/4885RIPK1 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.